Ysios leads €36.6m series-C for Sanifit

The fresh capital will enable the company to roll out the second phase of clinical trials for its SNF472 drug, which is used in the treatment of cardiovascular diseases linked to end-stage renal disease (ESRD).

On completion of the deal, Sanifit will also appoint Russell Greg, formerly president of GlaxoSmithKline’s corporate venturing arm, as chair.

Ysios is currently raising commitments for its second vehicle, a life sciences fund with a €100m target that held a first close on €51.8m in December 2014. The VC anticipates a final close for Ysios BioFund II by the end of 2015.

Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare, Edmond de Rothschild Investment Partners, La Caixa and Baxter Ventures also took part in the round, alongside existing investors.

Previous funding
La Caixa led a €3.6m round for Sanifit in August 2014 alongside HealthEquity, corporate backer Somtobir and the Nefrona Foundation.

Company
Founded in 2007 and headquartered in Palma de Mallorca, Sanifit develops drugs for use in patients suffering from cardiovascular diseases linked to ESRD. The pharmaceutical company has already undertaken 20 rounds of pre-clinical trials for SNF472, in addition to one round of clinical trials.

People
Joël Jean-Mairet is managing partner at Ysios. Joan Perelló is CEO of Sanifit.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Spain
• Ysios Capital